Evidence map›Paper›PMID 40535723›Full record

ArticleRegenerative therapy2025

Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling.

Tengfei Wu, Fang Wang, Changqing Ai, Li Li, Fan Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tengfei WuDepartment of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, China.
Fang WangDepartment of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, China.
Changqing AiDepartment of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, China.
Li LiDepartment of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, China.
Fan WuDepartment of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Postmenopausal osteoporosis is characterized by osteoclast differentiation and bone loss. Tangeretin (TGN) is a natural product that possesses multiple pharmacological properties. However, its specific function in postmenopausal osteoporosis deserves further exploration. Methods: The Results: For Conclusion: TGN represses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling.

Indexed as

Notch signalingOsteoclast differentiationPostmenopausal osteoporosisTGN

Identifiers

PMID40535723
PMCPMC12173807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.